stockrow
Monday 9 November 2026
Export ABOS’s income statement to Excel — free account
Acumen Pharmaceuticals, Inc.
ABOS- EPS
- +20.3%
- Free cash flow
- +12.6%
- Total debt
- −14.3%
Quarter to September 2026, against a year earlier
0.22
0.01
+4.76%
Follow ABOS
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(96.20%) | (93.23%) | (120.50%) | (162.72%) | |
| (67.07%) | (67.01%) | (72.97%) | (91.28%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(131.54%) | (109.06%) | (152.98%) | (259.60%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(1.91) | (1.67) | (1.27) | (1.22) | |
Free Cash Flow |
(115.63) | (105.54) | (91.79) | (87.95) | |
Capital Expenditures |
(0.09) | — | — | — | |
| Other line items | |||||
Cash ROIC |
(52.93%) | (42.74%) | (46.12%) | (63.05%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(29.32) | (26.84) | (24.41) | (24.65) | |
Operating CF/Net income |
0.95 | 0.93 | 0.87 | 0.85 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.14 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.91) | (1.67) | (1.27) | (1.22) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | — | — | — |
Columns are period end dates · fundamentals updated 2 Nov 2026